ERBB2 and gastric cancer: Another study found that using PI3K/MAPK inhibitors, copanlisib/refametinib in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer alone or in combination with anti-HER2 therapy can significantly improve patient response to these therapies [150].